×

Research and Markets: Hemophilia B - Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/jzd66w/hemophilia_b) has announced the addition of Global Markets Direct's new report "Hemophilia B - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Hemophilia B - Pipeline Review, H2 2012', provides an overview of the Hemophilia B therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia B.

Scope

- A snapshot of the global therapeutic scenario for Hemophilia B.

- A review of the Hemophilia B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Hemophilia B pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hemophilia B.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Hemophilia B therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/jzd66w/hemophilia_b.

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source: Research and Markets